CYSLTR1 and malignant colon neoplasm: Montelukast restricted the motility of 5-FU-resistant colon cancer cells, sensitized them to 5-FU and decreased 5-FU-resistance-derived stemness, suggesting that inhibition of CysLT1R signaling with montelukast might reverse drug resistance of colon cancer [87].